selenocysteine has been researched along with Osteogenic Sarcoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Li, X; Meng, FB; Wang, W; Wang, ZX; Zhou, DS | 1 |
Guo, HH; Huang, G; Li, JC; Shen, JN; Xu, MH; Yong, BC | 1 |
2 other study(ies) available for selenocysteine and Osteogenic Sarcoma
Article | Year |
---|---|
Selenocysteine inhibits human osteosarcoma cells growth through triggering mitochondrial dysfunction and ROS-mediated p53 phosphorylation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Mice, Nude; Mitochondria; Osteosarcoma; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; S Phase Cell Cycle Checkpoints; Selenocysteine; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
Analysis of Selenium Levels in Osteosarcoma Patients and the Effects of Se-Methylselenocysteine on Osteosarcoma Cells In Vitro.
Topics: Adolescent; Adult; Aged; Anticarcinogenic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Child; Drug Evaluation, Preclinical; Female; Genes, bcl-2; Humans; Male; Middle Aged; Osteosarcoma; Selenium; Selenocysteine; Young Adult | 2015 |